A unified definition of clinical anthracycline resistance breast cancer

British Journal of Cancer

Volumn 82, Issue 3, 2000, Pages 529-534

  Pivot, X ^a   Asmar, L ^b   Buzdar, A U ^b   Valero, V ^b   Hortobagyi, G ^b  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anthracycline resistance; Breast cancer; Clinical definition

Indexed keywords

AMSACRINE; ANTHRACYCLINE; ASPARAGINASE; BISANTRENE; CISPLATIN; DIACETOXYSCIRPENOL; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MELPHALAN; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NAVELBINE; PACLITAXEL; PENTOSTATIN; PEPTICHEMIO; TENIPOSIDE; VINBLASTINE; VINDESINE;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 0033953330     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.0958     Document Type: Article

References (24)

1. Creech R, Catalano R, Shah M and Dayal H (1993) An effective low-dose mitomycin regimen for hormonal- and chemotherapy-refractory patients with metastatic breast cancer. Cancer 51: 1034-1040
2. Degardin M, Bonneterre J, Hecquet B, Pion JM, Adenis A, Horner D and Demaille A (1994) Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 5: 423-426
3. De Vita V (1993) Biochemical resistance to chemotherapy is the major impediment to successful treatment. In: Cancer: Principles and Practice of Oncology, De Vita V, Hellman S and Rosenberg S (eds), pp. 281-283. Lippincott: Philadelphia
4. Henderson C (1991) Chemotherapy for metastatic disease. In: Breast Disease, Harris J, Hellman S, Henderson C and Kinne D (eds), pp. 604-665. Lippincott: Philadelphia
5. Holmes A, Valero V, Walters R, Theriault R, Booser D, Fraschini G, Buzdar A, Frye D, Gibbs H and Hortobagyi G (1993) The MD Anderson Cancer Center experience with Taxol in metastatic breast cancer. Cancer 15: 161-169
6. Hortobagyi G (1995a) Management of breast cancer: status and future trends. Semin Oncol 22: 101-107
7. Hortobagyi G (1995b) Future directions for vinorelbine (Navelbine). [Review]. Semin Oncol 22: suppl 2: 80-86
8. Hortobagyi G and Buzdar A (1991) Locally advanced breast cancer: a review including the MD Anderson experience. In: High-risk Breast Cancer, Ragaz J and Ariel I (eds) pp. 382-415. Springer-Verlag: Berlin
9. Hortobagyi G and Buzdar A (1993) Present status of anthracyclines in adjuvant treatment of breast cancer [Review]. Drugs 45, suppl 2: 10-19
10. Hortobagyi G and Buzdar A (1995) Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. CA Cancer 45: 199-226
11. Hortobagyi G, Smith T, Legha S, Swenerton K, Gehan E, Yap H, Buzdar A and Blumenschein G (1983) Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 12: 776-786
12. Jones S, Winner E, Vogel C, Laufman L, Hutchins L, O'Rourke M, Lembersky B, Budman D, Bigley J and Hohneker J (1995) Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13: 2567-2574
13. Kaplan E and Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
14. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170
15. Munzone E, Capri G, Fulfaro F, Tarenzi E, Caraceni A, Villani F, Spreafico C, Laffranchi A, Crabeels D and Gianni L (1994) Paclitaxel by 3 H schedule in relapsed breast cancer resistant to anthracycline. Ann Oncol 5: 43 (abstract 212).
16. Nabholtz J, Gelmon K, Bontenal M, Spielmann M, Clavel M, Seeber S, Conte P, Boneterre J, Fumoleua P, Slukes A, Sauter C, Roche H, Calvert H, Kaufman J, Chazard M, Diergarten K, Gallant G, Thompson M, Winograd B, Onetto N and Bristol-Myers Squibb Taxol Study Group (1993) Randomized trial of two doses of taxol in metastatic breast cancer: an interim analysis. Proc Am Soc Clin Oncol 12: 60 (abstract 42)
17. Pivot X, Asmar L and Hortobagyi G (1999) The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer. Int J Oncol 15: 381-386
18. Radvin P, Burris H, Cook G, Eisenberg P, Kane M, Bierman W, Mortimer J, Genevois E and Gellet R (1995) Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13: 2879-2885
19. Seidman A, Norton L, Reichman B, Crown J, Yao T, Heelan R, Hakes T, Lebwohl D, Gilewski T and Surbone A (1993) Preliminary experience with paclitaxel plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer. Semin Oncol 20: 40-45
20. Valero V, Holmes F, Waters R, Theriault R, Esparza L, Fraschini G, Fonseca G, Bellet R, Buzdar A and Hortobagyi G (1995) Phase II trial of docetaxel: a new, highly effective antineoplasic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13: 2886-2894
21. Vermoken JB, Ten Bokkel Huinink W, Mandjes I, Postman T, Huizing T, Heimans J, Beijnen J, Bierhorst F, Winograd B and Pinedo H (1995) High dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast carcinoma refractory to anthracycline therapy: a European Cancer Center trial. Semin Oncol 22: 16-22
22. Walters R, Frye D, Buzdar A, Holmes F and Hortobagyi G (1992) A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma. Cancer 69: 476-481
23. Wilson W, Berg S, Bryant G, Wittes R, Bates S, Fojo A, Steinberg S, Goldspiel B, Herdt J, O'Shaughnessy J, Balis F and Chabner B (1994) Paclitaxel in doxorubicin-refractory or mitaxantrone refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 12: 1621-1629
24. Yau J, Yap Y, Buzdar A, Hortobagyi G, Bodey G and Blumenschein G (1985) A comparative randomized trial of vinca-alcaloïds in patients with metastatic breast carcinoma. Cancer 55: 337-340